Minerva Neurosciences (NASDAQ:NERV) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Minerva Neurosciences (NASDAQ:NERV) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12), Zacks reports.

Minerva Neurosciences Trading Down 2.0 %

NERV traded down $0.06 on Wednesday, reaching $2.88. The company had a trading volume of 6,336 shares, compared to its average volume of 69,652. The company has a fifty day moving average of $3.15 and a 200-day moving average of $3.92. The company has a market capitalization of $20.14 million, a P/E ratio of -0.66 and a beta of 0.15. Minerva Neurosciences has a one year low of $2.26 and a one year high of $13.49.

Wall Street Analyst Weigh In

NERV has been the subject of several recent research reports. HC Wainwright lowered their price target on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating for the company in a research report on Thursday, May 2nd. StockNews.com assumed coverage on shares of Minerva Neurosciences in a research report on Tuesday. They set a “sell” rating for the company.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.